These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. [Allergen-derived peptide: A promising approach in asthma]. Klein M; Magnan A; Bouchaud G Rev Mal Respir; 2019 Apr; 36(4):442-446. PubMed ID: 31006580 [TBL] [Abstract][Full Text] [Related]
7. [Causal treatment of allergic bronchial asthma. Allergen elimination and hyposensitization]. Wüthrich B Schweiz Rundsch Med Prax; 1986 Jan; 75(5):83-8. PubMed ID: 3952411 [No Abstract] [Full Text] [Related]
8. Dose dependence of efficacy but not of safety in sublingual immunotherapy. Frati F; Incorvaia C; Marcucci F; Sensi L; Di Cara G; Puccinelli P; Dal Bo S Monaldi Arch Chest Dis; 2006 Mar; 65(1):38-40. PubMed ID: 16700192 [TBL] [Abstract][Full Text] [Related]
9. [Allergen-specific immunotherapy (hyposensitization). Part 1. Basics and subcutaneous application]. Klimek L HNO; 2000 Jan; 48(1):59-67. PubMed ID: 10663053 [No Abstract] [Full Text] [Related]
10. Is Allergen Immunotherapy in Children Disease Modifying? A Review of the Evidence. Rudman Spergel AK; Minnicozzi M; Wheatley LM; Togias A Curr Allergy Asthma Rep; 2018 Jul; 18(9):47. PubMed ID: 29995257 [TBL] [Abstract][Full Text] [Related]
11. Impact of allergen immunotherapy in allergic asthma. Zhang W; Lin C; Sampath V; Nadeau K Immunotherapy; 2018 Jun; 10(7):579-593. PubMed ID: 29569506 [TBL] [Abstract][Full Text] [Related]
12. Immunotherapy in allergic respiratory diseases. Vervloet D; van der Brempt X; Charpin D; Birnbaum J Lung; 1990; 168 Suppl():1013-24. PubMed ID: 2117102 [TBL] [Abstract][Full Text] [Related]
13. Systemic tolerability of specific subcutaneous immunotherapy with index-of-reactivity-standardized allergen extracts administered using clustered regimens: a retrospective, observational, multicenter study. Serrano P; Justicia JL; Sánchez C; Cimarra M; Fernández-Távora L; Orovitg A; Moreno C; Guerra F; Alvà V Ann Allergy Asthma Immunol; 2009 Mar; 102(3):247-52. PubMed ID: 19354072 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Subcutaneous and Sublingual Immunotherapy for Allergic Rhinoconjunctivitis and Asthma. Roxbury CR; Lin SY Otolaryngol Clin North Am; 2017 Dec; 50(6):1111-1119. PubMed ID: 28964530 [TBL] [Abstract][Full Text] [Related]
16. Rush injection therapy for asthma and allergic rhinitis. Greenberger PA Ann Allergy; 1994 Nov; 73(5):378-80. PubMed ID: 7978528 [No Abstract] [Full Text] [Related]
18. Immunotherapy with a depigmented, polymerized vaccine of Olea europaea pollen allergens. Significantly reduces specific bronchial and skin test reactivity in sensitized patients after one year of treatment. Guerra F; Daza JC; Almeda E J Investig Allergol Clin Immunol; 2003; 13(2):108-17. PubMed ID: 12968395 [TBL] [Abstract][Full Text] [Related]
19. [Sublingual vs subcutaneous immunotherapy]. Olivé Pérez A Rev Alerg Mex; 2004; 51(1):29-35. PubMed ID: 15119753 [TBL] [Abstract][Full Text] [Related]
20. [Apropos of sublingual specific immunotherapy]. Sabbah A Allerg Immunol (Paris); 1998 Apr; 30(4):97-8. PubMed ID: 9631689 [No Abstract] [Full Text] [Related] [Next] [New Search]